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n many ways, the surgical management in tetralogy of Fallot (TOF) is the poster child for the development of congenital cardiac surgery, with progressive evolution leading to the current era when early complete repair carries an exceptionally low mortality. Consequently, there are more adults with the diagnosis than children. 1 However, these triumphs have been tarnished by the realization that our patients have a continuous late hazard of impaired functional status, heart failure, arrhythmias, and death, at least in part related to the consequences of residual right ventricular (RV) outflow tract dysfunction. 2 We have come a long way in the past 3 decades, from initially considering residual pulmonary incompetence as a benign aftermath of repair to the understanding of its central role in the pathogenesis of many late adverse consequences. As a result, pulmonary valve replacement (PVR), once rarely performed, is considered inevitable for many patients. It is now, of course, all about timing. 2, 3 If there were no adverse consequences to PVR, the timing question would be irrelevant, but although the clock is inevitably ticking for many with postoperative RV outflow tract dysfunction, a different clock starts ticking after PVR.
How, then, should we decide when to intervene? Because of the relatively low incidence of adverse outcomes to support statistically significant associations in small groups of patients with repaired TOF, current guidelines for timing of surgical PVR in the asymptomatic patient have depended on preoperative markers of poor ventricular remodeling after surgery, heavily focusing on thresholds of RV size and systolic function. 2, 3 Although largely addressing a different patient population and with a different inherent risk/benefit profile, timing for transcatheter PVR is often inferred from surgical PVR guidelines. 3 Such recommendations have been based on the not unreasonable assumption that reverse remodeling of the RV to normal is desirable, and by defining a threshold of irreversibility, we might prevent the later adverse consequences of chronic pulmonary incompetence. The ugly fact that gets in the way of this beautiful theory is that although the RV can be expected to reverse remodel and some improvement in functional capacity often results, to date, a survival benefit after either surgical or transcatheter PVR, when guided by these indexes, has not been demonstrated. [2] [3] [4] Geva and colleagues 5 are to be commended for their current multicenter IN-DICATOR cohort observational study (International Multicenter TOF Registry) of patients with repaired TOF, describing preoperative risk factors for postoperative occurrence of death or sustained ventricular tachycardia after PVR, as well as associations with the secondary outcomes of significant heart failure and sustained atrial tachyarrhythmias. This is the first study to meticulously investigate post-PVR outcomes in a relatively large cohort. 5 Primary outcome predictors included pre-PVR RV systolic dysfunction, elevated RV mass-to-volume ratio, and age at PVR ≥28 years, with increased RV systolic pressure proving predictive in a subgroup echocardiographic analysis. RV end-diastolic volume, a common focus of attention in current clinical practice, was not associated with outcomes. Does this mean that we should abandon RV volumetric criteria in helping to guide timing of PVR in the asymptomatic patient? Although the authors recognize that the findings in this observational study are hypothesis-generating, clear questions are raised about the current management of asymptomatic patients. The 3 main findings related to the primary outcomes are not themselves surprising, with similarities to the initial INDICATOR cohort analysis of all patients regardless of PVR status, 6 and likely are related to the deteriorating health of the myocardium.
This strong correlation of the hypertrophied and dysfunctional RV in the aging patient with poor outcomes lends support to a better understanding of both the relationship to, and the effects of, RV diastolic dysfunction and diffuse interstitial fibrosis, 3, 7 questions that the current INDICATOR cohort study was not designed to answer. Although they undoubtedly are flawed, before abandoning current guidelines, we need much more information on the preoperative pathogenesis and postoperative modification of these risk factors for poor outcomes before using them clinically to define the need for and timing of PVR. In essence, we need to know whether they are statistically defined risk factors or true biomarkers of pathogenesis and outcome. For example, it is well documented that although RV end-diastolic volume improves after PVR, RV ejection fraction (EF), which is clearly associated with poor outcomes, does not, especially after surgical PVR.
3,4 Clearly, we cannot offer every patient with a normal RV EF a PVR on the basis that if it becomes abnormal, and therefore a harbinger of poor outcomes, surgery will then fail to improve it. However, assuming its deterioration is progressive and at some stage reversible, that is, it is a "biomarker" of outcome, is there a threshold of RV EF below which the argument for intervention based on improved later survival can be sustained? We are clearly a long way from answering that question. Similarly, is RV mass-to-volume ratio a modifiable biomarker or a static risk factor? Just as with reduced RV EF, it may be present at an early age after initial complete repair. 8 Would earlier PVR modify the RV mass-to-volume ratio in a way that would allow it to be confirmed as a robust biomarker of subsequent outcome? Furthermore, even if early initial valve implantation might improve outcomes, what would be the lifetime cost of recurrent interventions once we start the new clock ticking?
Just as with RV volumes, any new index we use is likely to be flawed, and what of the other potential risk factors and biomarkers of poor post-PVR outcomes that have been identified? The surprising finding in the present study was the lack of association of both left ventricular (LV) systolic function and QRS duration with the primary outcomes. 5 In the initial INDICATOR cohort analysis of all repaired TOF, LV EF z score less than −2 was 1 of 3 main associations with the primary outcomes. 6 This was similar to findings from the CONCOR registry (Congenital Corvitia) of patients with repaired TOF regardless of whether they had received a PVR, in whom RV and LV systolic dysfunction was linked to adverse outcomes. 9 In the present study, 5 the authors acknowledge that their data may be underpowered to demonstrate a statistical association, but the potential impact of LV dysfunction on outcomes should not be ignored. We have recently highlighted the important interventricular interactions in those with repaired TOF. 7 Left ventricular systolic dysfunction is clearly associated with impaired clinical status, and LV systolic dysfunction, including that revealed by deformational imaging, has been linked to adverse outcomes. 3, 7 In addition, invasively measured LV end-diastolic pressure emerged as a powerful predictor of appropriate shocks in patients with repaired TOF with implantable cardioverter-defibrillators. 10 Therefore, future studies focusing on those undergoing PVR will need to reassess the likely importance of both LV systolic and diastolic function in decision-making for PVR. 3, 7 Furthermore, although QRS duration had a borderline association with primary outcomes in both the initial 6 and present INDICATOR cohort study, 5 it was not a predictor after multivariable analysis, similar to results in the CONCOR registry. 9 These findings superficially appear to conflict with earlier non-imaging-based studies that reported a strong correlation between rapidly increasing QRS duration pre-PVR 11 and failure of QRS duration to decrease post-PVR on adverse outcomes. 12 However, although multivariable analysis may statistically exclude QRS duration as a primary risk factor for poor outcomes, which is entirely understandable given the nature of the measurement (itself influenced variably by other risk factors), might it still be a facile composite biomarker (an "erythrocyte sedimentation rate" of the ventricular mass?) that can be used in day-to-day practice?
All this said, perhaps all the currently defined risk factors or biomarkers of poor outcomes are merely secondary indicators of a more fundamental abnormality of myocardial biology. Although clearly speculative, myocardial fibrosis (itself a generic outcome of multiple diverse myocardial insults) is emerging as a highly important adverse risk factor and therapeutic target in many cardiovascular diseases. Now measurable by cardiac magnetic resonance as a presumed surrogate of diffuse interstitial fibrosis, increased extracellular volume in postoperative patients with TOF has been demonstrated to correlate not only with poor outcomes but also with decreasing RV EF and increasing RV volume loading. 7, 13 Detrimental interventricular interactions are also reflected by changes in extracellular volume, with RV extracellular volume correlating with LV extracellular volume and increasing RV dilation correlating with both LV systolic and diastolic dysfunction. 7 It is clearly premature to suggest that myocardial fibrosis is the root of all tetralogy evils, but it seems likely that it will become part of the decision-making algorithm in the future, and its true place as a biomarker will likely be established only through large data sets generated by multicenter consortia such as the INDICATOR cohort.
So, where do we go from here? Unfortunately, although enlightening and question-raising, the current INDICATOR cohort report does not provide the basis for a fundamental change in the PVR guidelines, however flawed. There is room for considerable optimism, however. The development of large multicenter and national data sets such as the INDICATOR cohort will surely allow us to better define and refine the use of risk factors and biomarkers of failure, old and new, to make our patients' clock tick a little more slowly and, we hope, longer in the future.
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